Pharmaceutical

“At the FDA’s request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,” an HHS spokesperson told Fierce P...

One analyst speculated that, going forward, Prasad may be less “heavy-handed” in reviewing rare disease therapies given the public backlash to the age...

Genmab and AbbVie have presented new data that could help grow the reach of their blood cancer drug Epkinly in follicular lymphoma. The partners are a...

In this episode of "The Top Line," we examine the latest Most Favored Nation drug pricing pressures in the U.S., how pharma is responding and why part...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs may eventually reach 250%....

Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.S. The deal will see BioNTech pay out cash and extend r...

After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona in certain CALD patients...

While most of Gilead’s second-quarter presentation focused on its excitement over the launch of game-changing HIV PrEP drug Yeztugo, there was a disqu...

“Free Mind” is the first public health campaign launched by the CDC since Robert F. Kennedy Jr. was appointed secretary of the U.S. Department of Heal...

Zongertinib got an accelerated approval for previously treated non-small cell lung cancer patients who have the relatively rare HER2 tyrosine kinase d...